Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C23H27N3O4.ClH |
| Molecular Weight | 445.939 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.NC(=N)NC[C@H]1CC[C@@H](CC1)C(=O)OC2=C(C=CC=C2)C(=O)OCC3=CC=CC=C3
InChI
InChIKey=ZNYYFCHDQJQKOK-AELULUIVSA-N
InChI=1S/C23H27N3O4.ClH/c24-23(25)26-14-16-10-12-18(13-11-16)21(27)30-20-9-5-4-8-19(20)22(28)29-15-17-6-2-1-3-7-17;/h1-9,16,18H,10-15H2,(H4,24,25,26);1H/t16-,18-;
DescriptionSources: http://www.e-ce.org/upload/pdf/29400520.pdfCurator's Comment: description was created based on several sources, including, http://www.ncbi.nlm.nih.gov/pubmed/27446246
Sources: http://www.e-ce.org/upload/pdf/29400520.pdf
Curator's Comment: description was created based on several sources, including, http://www.ncbi.nlm.nih.gov/pubmed/27446246
Benexate is an active ingredient of benexate.CD or benexate hydrochloride betadex, a beta-cyclodextrin complex. Benexate was approved for the treatment of Gastric Ulcer in Japan. The terapeuthic effect of benexate is associated with promotion of prostaglandin synthesis, inhibition of acid secretion and increase in mucosal blood flow.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: GO:0001516 Sources: http://www.ncbi.nlm.nih.gov/pubmed/27446246 |
|||
Target ID: GO:0001696 Sources: http://www.ncbi.nlm.nih.gov/pubmed/27446246 |
|||
Target ID: GO:1990768 Sources: http://www.ncbi.nlm.nih.gov/pubmed/27446246 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | ULGUT Approved UseUnknown |
|||
| Primary | ULGUT Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Benexate hydrochloride betadex modulates nitric oxide synthesis and cytokine expression in gastric ulcers. | 2016-08 |
|
| Differential effect of benexate hydrochloride betadex on prostaglandin levels in stomach and inflammatory site in rats. | 1996-10 |
|
| In-vitro and in-vivo antibacterial activity of plaunotol, a cytoprotective antiulcer agent, against Helicobacter pylori. | 1996-05 |
|
| Syntheses and inhibitory effects on gastric lesions of trans-guanidinomethylcyclohexane carboxylic acid arylamides. | 1993-03 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://notendur.hi.is/thorstlo/cyclodextrin.pdf
Unknown
Route of Administration:
Oral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
m2310
Created by
admin on Mon Mar 31 18:50:57 GMT 2025 , Edited by admin on Mon Mar 31 18:50:57 GMT 2025
|
PRIMARY | Merck Index | ||
|
100000085015
Created by
admin on Mon Mar 31 18:50:57 GMT 2025 , Edited by admin on Mon Mar 31 18:50:57 GMT 2025
|
PRIMARY | |||
|
QVN4YYK2C6
Created by
admin on Mon Mar 31 18:50:57 GMT 2025 , Edited by admin on Mon Mar 31 18:50:57 GMT 2025
|
PRIMARY | |||
|
SUB00700MIG
Created by
admin on Mon Mar 31 18:50:57 GMT 2025 , Edited by admin on Mon Mar 31 18:50:57 GMT 2025
|
PRIMARY | |||
|
78718-25-9
Created by
admin on Mon Mar 31 18:50:57 GMT 2025 , Edited by admin on Mon Mar 31 18:50:57 GMT 2025
|
PRIMARY | |||
|
DTXSID80999968
Created by
admin on Mon Mar 31 18:50:57 GMT 2025 , Edited by admin on Mon Mar 31 18:50:57 GMT 2025
|
PRIMARY | |||
|
m2310
Created by
admin on Mon Mar 31 18:50:57 GMT 2025 , Edited by admin on Mon Mar 31 18:50:57 GMT 2025
|
PRIMARY | Merck Index |
ACTIVE MOIETY
SUBSTANCE RECORD